Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC)-MedSci.cn

Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC)

Finn, RS; Kudo, M; Cheng, AL; Wyrwicz, L; Ngan, R; Blanc, JF; Baron, AD; Vogel, A; Ikeda, M; Piscaglia, F; Han, KH; Qin, S; Minoshima, Y; Funahashi, Y; Ren, M; Dairiki, R; Sachdev, P; Tamai, T; Dutcus, C; Evans, TRJ

ANNALS OF ONCOLOGY, 2017; 28 ( ):

科室
- - 订阅+
  - 更多科室
工具
服务